VIOLIN Logo
Cov19VaxKB Banner
Search: for Help
Home
Introduction
Statistics
Authorized Vaccines
Phase III Vaccines
Phase II Vaccines
Phase I Vaccines
Preclinical Vaccines
Vaccine Safety
Vaccine Design
News
Data Submission
Data Exchange
Data Download
Links
Documentation
Updates
Acknowledgements
FAQs
Disclaimer
Contact Us
UMMS Logo

Phase III COVID-19 Vaccines

This site collects existing Phase III COVID-19 vaccines around the world as of February 17, 2021.

Existing vaccines in Phase III clinical trials include:

  1. Ad26.COV2.S
    • Other names: JNJ-78436735
    • Clinical trial ID:
      • Phase III: NCT04505722 (protocol)
        • Age subgroups: 18-59 years, 60 years and above
        • Location: USA, Argentina, Brazil, Chile, Colombia, Mexico, Peru, Philippines, South Africa, Ukraine
      • Phase III: NCT04614948
        • Age subgroups: 18 years and above
        • Location: USA, Belgium, Colombia, France, Germany, Philippines, South Africa, Spain, UK
    • Type: Recombinant vector vaccine
    • Manufacturer: Janssen Pharmaceutica
    • Publications:
      • Bos et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020; 5; 91. [PubMed: 33083026].
      • Mercado et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020; ; . [PubMed: 32731257].
    • VIOLIN: 5782
    • VO: VO_0005159
  2. AG0301-COVID19
    • Clinical trial ID:
      • Phase II/III: NCT04655625
        • Age subgroups: 18 years and above
        • Location: Japan
    • Type: DNA vaccine
    • Manufacturer: AnGes, Inc.
    • VIOLIN: 5780
    • VO: VO_0005165
  3. COVID-19 inactivated virus vaccine by Chinese Academy of Medical Sciences
    • Clinical trial ID:
      • Phase III: NCT04659239
        • Age subgroups: 18 years and above
        • Location: Brazil, Malaysia
    • Type: Inactivated or “killed” vaccine
    • Manufacturer: Institute of Medical Biology, Chinese Academy of Medical Sciences
    • VIOLIN: 5785
    • VO: VO_0005167
  4. COVID-19 inactivated virus vaccine by Wuhan Institute of Biological Products
    • Clinical trial ID:
      • Phase III: ChiCTR2000034780
        • Age subgroups: Healthy adults aged 18 years and above
        • Location: UAE
      • Phase III: ChiCTR2000039000
        • Age subgroups: Healthy adults aged 18 years and above
        • Location: Morocco
      • Phase III: NCT04510207
        • Age subgroups: 18 years and above
        • Location: Bahrain, Egypt, Jordan, UAE
      • Phase III: NCT04612972
        • Age subgroups: Healthy adults aged 18 years and above
        • Location: Peru
      • Phase I/II: ChiCTR2000031809 (protocol)
        • Age subgroups: 6 years and above
        • Location: China
    • Type: Inactivated or “killed” vaccine
    • Manufacturer: Wuhan Institute of Biological Products; Sinopharm
    • Publications:
      • Xia et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020; 324(10); 1–10. [PubMed: 32789505].
    • VIOLIN: 5775
    • VO: VO_0005160
  5. CoVLP
    • Clinical trial ID:
      • Phase II/III: NCT04636697
        • Age subgroups: 18-64 years, 65 years and above
        • Location: Canada
    • Type: Virus-like particle
    • Manufacturer: Medicago Inc.
    • VIOLIN: 5796
    • VO: VO_0004992
  6. CVnCoV
    • Clinical trial ID:
      • Phase III: EUCTR2020-004066-19
        • Age subgroups: 18-64 years, 65 years and above
        • Location: Germany
      • Phase II/III: NCT04652102
        • Age subgroups: 18-64 years, 65 years and above
        • Location: Germany
    • Type: mRNA vaccine
    • Manufacturer: CureVac AG
    • VIOLIN: 5786
    • VO: VO_0005168
  7. INO-4800
    • Clinical trial ID:
      • Phase II/III: NCT04642638
        • Age subgroups: 18 years and above
        • Location: USA
    • Type: DNA vaccine
    • Manufacturer: Inovio Pharmaceuticals
    • Publications:
      • Tebas et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine. 2020; 100689; . [PubMed: 33392485].
      • Smith et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020; 11(1); 2601. [PubMed: 32433465].
    • VIOLIN: 5793
    • VO: VO_0005172
  8. NVX-CoV2373
    • Clinical trial ID:
      • Phase III: NCT04583995 (protocol)
        • Age subgroups: 18-64 years, 65-84 years
        • Location: UK
      • Phase III: NCT04611802
        • Age subgroups: 18 years and above
        • Location: USA, Mexico, Puerto Rico
    • Type: Nanoparticle vaccine
    • Manufacturer: Novavax
    • Publications:
      • Guebre-Xabier et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020; 38(50); 7892-7896. [PubMed: 33139139].
      • Keech et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020; ; . [PubMed: 32877576].
    • VIOLIN: 5791
    • VO: VO_0005155
  9. SCB-2019
    • Clinical trial ID:
      • Phase II/III: NCT04672395
        • Age subgroups: 18 years and above
    • Type: Subunit vaccine
    • Manufacturer: Clover Biopharmaceuticals, GSK, Dynavax
    • Publications:
      • Richmond et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021; S0140-6736(21)00241-5; . [PubMed: 33524311].
    • VIOLIN: 5797
    • VO: VO_0004994
  10. UB-612
    • Clinical trial ID:
      • Phase II/III: NCT04683224
        • Age subgroups: 18-59 years, 60 years and above
    • Type: Subunit vaccine
    • Manufacturer: COVAXX, United Biomedical Inc. Asia
    • VIOLIN: 5798
    • VO: VO_0004995
  11. ZF2001
    • Other names: RBD-Dimer
    • Clinical trial ID:
      • Phase III: NCT04646590
        • Age subgroups: 18-59 years, 60 years and above
        • Location: China
    • Type: Subunit vaccine
    • Manufacturer: Anhui Zhifei Longcom Biopharmaceutical; Institute of Microbiology, Chinese Academy of Sciences
    • Publications:
      • Dai et al. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell. 2020; 182(3); 722-733. [PubMed: 32645327].
    • VIOLIN: 5764
    • VO: VO_0005142

Provenance: All data in Cov19VaxKB originates from manual curation of reliable resources.

Note: The page was updated on February 17, 2021. We plan to update this page on a weekly or even a daily basis. Please provide us with any new information that you believe would be useful if included on the website.